BR112018006474A2 - nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo - Google Patents

nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo

Info

Publication number
BR112018006474A2
BR112018006474A2 BR112018006474A BR112018006474A BR112018006474A2 BR 112018006474 A2 BR112018006474 A2 BR 112018006474A2 BR 112018006474 A BR112018006474 A BR 112018006474A BR 112018006474 A BR112018006474 A BR 112018006474A BR 112018006474 A2 BR112018006474 A2 BR 112018006474A2
Authority
BR
Brazil
Prior art keywords
ophthalmic composition
rebamipide
preparing
same
new ophthalmic
Prior art date
Application number
BR112018006474A
Other languages
English (en)
Inventor
Lee Dong-Ha
Cho Eui-Hwan
Shin Hee-Jong
Choi Mee-Hwa
Ki Min-Hyo
Choi Sung-Ju
Lee Sung-Woo
Original Assignee
Samjin Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samjin Pharm Co Ltd filed Critical Samjin Pharm Co Ltd
Publication of BR112018006474A2 publication Critical patent/BR112018006474A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

a presente invenção proporciona uma nova composição oftálmica compreendendo rebamipide e um método para preparar o mesmo. a composição oftálmica da presente invenção mantém sua transparência por um longo tempo, mesmo em uma faixa de ph de fisiologicamente neutro a fracamente básico que não prejudica a córnea e a conjuntiva de um paciente que sofre de olho seco e com estabilidade melhorada para não seja re-dispersado.
BR112018006474A 2015-10-01 2016-09-30 nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo BR112018006474A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150138349A KR20170039347A (ko) 2015-10-01 2015-10-01 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
PCT/KR2016/011015 WO2017057973A1 (en) 2015-10-01 2016-09-30 Novel ophthalmic composition comprising rebamipide and method for preparing the same

Publications (1)

Publication Number Publication Date
BR112018006474A2 true BR112018006474A2 (pt) 2018-10-09

Family

ID=58423846

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006474A BR112018006474A2 (pt) 2015-10-01 2016-09-30 nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo

Country Status (10)

Country Link
US (1) US10918725B2 (pt)
EP (1) EP3355929A4 (pt)
JP (1) JP6625206B2 (pt)
KR (1) KR20170039347A (pt)
CN (1) CN108136036A (pt)
BR (1) BR112018006474A2 (pt)
CA (1) CA3000634C (pt)
MX (1) MX2018003799A (pt)
RU (1) RU2706353C1 (pt)
WO (1) WO2017057973A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR102615076B1 (ko) 2021-07-14 2023-12-19 대우제약 주식회사 안정한 레바미피드 점안제의 대용량 제조 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0616547A (ja) * 1992-07-01 1994-01-25 Wakamoto Pharmaceut Co Ltd 消炎点眼剤
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
AR004214A1 (es) 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
KR20040104020A (ko) * 2003-06-02 2004-12-10 진양제약주식회사 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
TWI363626B (en) * 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
CN101081211A (zh) * 2006-06-02 2007-12-05 北京万鹏朗格医药科技有限公司 水难溶性喹诺酮类化合物的注射剂及制备方法
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
WO2008074853A1 (en) 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
CN101778626B (zh) * 2007-08-10 2014-05-07 大塚制药株式会社 含有瑞巴派特的药物组合物
CN101959504A (zh) * 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
SI2285413T1 (sl) 2008-06-19 2012-09-28 Otsuka Pharma Co Ltd Farmacevtski sestavek
CN101757621B (zh) * 2008-11-28 2012-07-04 天津金耀集团有限公司 一种眼部抗炎的环糊精包合药物组合物
JP5639409B2 (ja) * 2009-08-07 2014-12-10 ロート製薬株式会社 シリコーンハイドロゲルコンタクトレンズ用眼科組成物
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
TW201322982A (zh) 2011-11-01 2013-06-16 Otsuka Pharma Co Ltd 用於治療前眼疾病之藥劑，該藥劑包含瑞巴派特及眼淚保持劑
CN102512420A (zh) * 2011-11-29 2012-06-27 北京阜康仁生物制药科技有限公司 一种以瑞巴派特的药用盐为活性成分的药用组合物
TW201417814A (zh) 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
CN104586762A (zh) * 2014-04-11 2015-05-06 广州仁恒医药科技有限公司 含有瑞巴派特的药物组合物及其制备方法
CN105147606A (zh) * 2015-08-18 2015-12-16 广州仁恒医药科技有限公司 一种瑞巴派特水悬浮液的制备方法
KR101718733B1 (ko) 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제

Also Published As

Publication number Publication date
WO2017057973A1 (en) 2017-04-06
JP2018531934A (ja) 2018-11-01
JP6625206B2 (ja) 2019-12-25
US10918725B2 (en) 2021-02-16
KR20170039347A (ko) 2017-04-11
CA3000634C (en) 2020-05-05
EP3355929A4 (en) 2019-06-19
MX2018003799A (es) 2018-09-12
CA3000634A1 (en) 2017-04-06
EP3355929A1 (en) 2018-08-08
RU2706353C1 (ru) 2019-11-18
US20180264120A1 (en) 2018-09-20
CN108136036A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
MX2022000754A (es) Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
CL2015003442A1 (es) Derivados heterociclicos
BR112016012968A2 (pt) Métodos e composições para o tratamento de condições associadas com o envelhecimento
MX2018010292A (es) Tratamiento de condiciones oculares alergicas con ciclodextrinas.
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2019003364A (es) Composiciones oftalmicas que comprenden ciclosporina.
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112017002963A2 (pt) derivados citotóxicos de benzodiazepina
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
PH12017500922A1 (en) Stabilized omega-3 ophthalmic compositions
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
BR112017005272A2 (pt) uso de cisteamina no tratamento de infecções causadas por leveduras/bolores
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements